 | ||||||||||||
|
| Oral thrush Oral thrush is a condition in which the fungus Candida albicans accumulates on the lining of your mouth. Oral thrush causes creamy white lesions, usually on your tongue or inner cheeks. The lesions can be painful and may bleed slightly when you scrape ... Manila Bulletin - Tue, 14 May 2013 15:21 | |
| Candidiasis oral, ¿qué es y cómo tratar? La candidiasis oral es una infección provocada por el crecimiento excesivo de un hongo llamado Candida albicans. Este microorganismo es bastante común y suele aparecer en la flora bucal de muchas personas. Sin embargo, cuando hay un crecimiento ... Terra Colombia - Tue, 14 May 2013 04:40 | |
 | Dealing with oral malador Acrylic dentures when kept in mouth at night and not regularly cleaned can produce a typical smell associated with candidiasis. Periodontal infection: Bacteria associated with gingivitis and periodontitis are all most gram negative and are known to ... Gulf Times - Tue, 14 May 2013 11:13 |
 | UPDATE 3-US FDA approves Glaxo/Theravance drug for COPD lung disease The most common side effects reported by patients were inflammation of the nasal passage, upper respiratory tract infections, headache and oral candidiasis, also known as thrush. The approval, which follows a more favorable-than-expected review by an ... Reuters - Fri, 10 May 2013 09:01 |
| BREO™ ELLIPTA™ gains US approval for the treatment of COPD Sacramento Bee - Fri, 10 May 2013 13:15 | |
| FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease FDA.gov - Fri, 10 May 2013 08:14 | |
| FDA Approves 'Son of Advair' for COPD Exacerbations Medscape - Fri, 10 May 2013 08:50 | |
| FDA Okays Theravance, Glaxo Drug To Treat COPD - Update RTT News - Fri, 10 May 2013 12:08 | |
| FDA Approves Breo Ellipta for COPD Pharmacy Practice News - Mon, 13 May 2013 08:54 | |
| GlaxoSmithKline's Inhaler Drug Gets FDA Approval; Once-A-Day Use Only Headlines & Global News - Sat, 11 May 2013 05:23 | |
| Assessing Your Asthma is Key to Taking Control ... common adverse reactions ≥3% reported in clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral ... Sacramento Bee - Mon, 13 May 2013 13:08 | |
| Not just a bad tissue issue These infections include yeast (vaginal candidiasis), bacterial infections like bacterial vaginosis, and infections caused by poor hygiene. Below is a list of other things that could cause you harm: 1. Inserting soap in the vagina. Blue soap (cake soap ... Jamaica Observer - Mon, 29 Apr 2013 01:48 | |
| US green light for Warner Chilcott's new contraceptive The oral contraceptive regimen consists of 24 white active chewable tablets that contain the active ingredients, followed by four brown non-hormonal placebo tablets containing ferrous fumarate. ... The pill was also found to be generally well-tolerated ... PharmaTimes - Fri, 10 May 2013 04:04 | |
| (BW) Theravance and Elan Enter Into a $1.0 Billion Royalty Participation ... ... reactions (>=3% and more common than in placebo) reported in two 6-month clinical trials with BREO ELLIPTA (and placebo) were nasopharyngitis, 9% (8%); upper respiratory tract infection, 7% (3%); headache, 7% (5%); and oral candidiasis, 5% (2%). Wall Street Journal (press release) - Sun, 12 May 2013 23:10 | |